In an added benefit, more than one in eight people taking the highest dose of Retratrutide were completely free of arthritic knee pain after 68 weeks

Seeking Alpha's roundup of statements, announcements, and remarks that could impact markets, sectors, or individual stocks. Read more here.

Eli Lilly and Co shared updated results of Inluriyo (imlunestrant) from a Phase 3 study in previously treated breast cancer patients.

In the world of oncology drug development, the standard playbook is simple: race to earlier lines of treatment, where patient populations are larger. | Despite holding positive phase 3 data that position its BTK inhibitor Jaypirca for a first-line approval in chronic lymphocytic leukemia,